AMS AMS-OSRAM AG

Elevating CT Technology: Photon Counting and Cost-Efficient Sensor Modules From ams OSRAM

With two new sensor modules, , a global leader in intelligent sensors and emitters, demonstrates its commitment to Computed Tomography (CT). At the heart of this diagnostic imaging technology are CT sensor modules that support clinical applications from oncology to the treatment of cardiovascular conditions, ensuring precise patient outcomes and enabling early diagnosis. The new products advance the medical imaging technology across the CT market segments. For the premium CT segment, ams OSRAM introduces a new System-in-Package sensor module designed for photon counting detectors, delivering a substantial reduction in the radiation dose and additional diagnostic value. For the price-sensitive CT segment, ams OSRAM presents a new sensor module, ensuring high-quality medical imaging at a competitive price.

“ams OSRAM is making both cutting-edge and cost-efficient sensor modules broadly available for high-resolution, information-rich, and low-dose CT scans. Our powerful but affordable sensor module enhances the accessibility of modern CT technology while delivering significant performance improvements. With its new photon counting detector, our company is playing a key role in driving the next revolution in medical imaging, elevating medical treatments to a new level,” emphasizes Ivo Ivanovski, Head of Product Line Medical Imaging & Foundry at ams OSRAM.

For more information on the , the first disruptive package solution for photon counting detectors and , an affordable, high-performance sensor module for 64-slice CT imaging, please refer to the .

EN
18/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AMS-OSRAM AG

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/28/2025

Tereos : -29% decline in EBITDA for 2024/25 and very cautious guidance for 2025/26, with leverage that could reach 5x.|IHO roadshow feedback: ContiTech monetisation could help IHO to de-lever… but earliest 2026|Emeria: Q1 2025 results reassuring despite ongoing liquidity concerns|Isabel Marant: despite a further improvement in the topline, EBITDA fell again in Q1|Tough 2025 results, withdrawal of 2026 targets, Q1 2026 revenue expected to drop by 20%, and new CFO|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 28/05/2025

Tereos : publication d’une baisse de -29% de l’EBITDA en 2024/25 et guidance très prudente pour 2025/26, avec un levier qui pourrait aller jusqu’à 5x.|IHO roadshow feedback: ContiTech monetisation could help IHO to de-lever… but earliest 2026|Emeria : un T1 2025 rassurant même si la liquidité reste critique|Isabel Marant : malgré une nouvelle amélioration de la topline, l’Ebitda est à nouveau en baisse au T1|Résultats 2025 difficiles, retrait des objectifs 2026, CA T1 2026 attendu en baisse org....

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/12/2025

Pharma: Donald Trump wants to cut the price of prescription drugs|ams OSRAM launches a consent request to amend the convertible notes|MPS published strong Q1 2025 results /the offer for Bacred is proceeding according to schedule|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 12/05/2025

Pharma : Donald Trump veut réduire le prix des médicaments sur ordonnance|ams OSRAM lance une demande de consentement visant les obligations convertibles|MPS a publié de solides résultats T1 2025 et poursuit son offre sur Mediobanca|

ResearchPool Subscriptions

Get the most out of your insights

Get in touch